In this webinar, our expert panel will explore the key medicolegal risks in prescribing ADHD medications, including documentation and compliance with controlled substances guidelines.
They’ll also discuss emerging challenges linked to evolving national policy and share practical strategies to help clinicians manage risk while maintaining safe, patient-focused care.
Learning outcomes
- At the end of this webinar, participants will be able to:
- Identify key medicolegal risks associated with prescribing ADHD medications.
- Discuss how changes in Australian prescribing regulations impact risk management and collaboration across healthcare teams.
- Plan strategies to mitigate risk and minimise medicolegal exposure.
